Kisolite Corp will pursue further academic and commercial research, including guidance from a Scientific Board, chaired by Roger Kuypers.
Considerable research results from five faculties at the University of British Columbia are only part of the assembly of knowledge regarding Kisolite’s mineral clay. Additional data from private commercial Labs, historical testing by MIT, as well as the traditional knowledge of the Heiltsuk First Nation, are all part of the understanding currently known to the company.
Future analysis will focus on commercialization, and the many roles the mineral may play as an ingredient for the new health paradigm. The Life Sciences industry segments within reach include biotech, medical device, and diagnostics companies. Applications in biopharmaceuticals and functional foods are being sought out with possible partners, part of the commercialization of Kisolite Corp’s IP assets. Kisolite Corp is pursuing an understanding of the geomicrobiology that spans from mountains to minerals to microbes, and from minerals to immunity. Roger Kuypers is Chairman of the Scientific Board for Kisolite Corp.
Roger Kuypers practices law at Faskens, Vancouver’s largest law firm, in the areas of life sciences and intellectual property law. He is the Chair of the region’s Life Sciences industry group and the Intellectual Property practice group. Roger advises businesses and institutions on the development, acquisition, and commercialization of technologies as well as corporate matters, finance, and acquisitions.
In the Life Sciences, his clients include biotech, medical device, and diagnostics companies. He has negotiated License and Research Agreements with universities in Canada and abroad. His practice includes negotiation of manufacture and supply agreements for pharmaceuticals and functional foods. IP expertise includes trademark and copyright applications, patent assignments and licensing. He conducts IP audits and provides strategic advice for the development, protection, and commercialization of IP assets.
Dr. Neil Branda, Ph.D. Chemistry, MIT
Neil Branda is a Professor of Chemistry and the Canada Research Chair in Materials Science at Simon Fraser University. He is also the Scientific Director of 4D LABS, a research center for advanced materials and nanoscale devices.
Dr. Neil Branda founded SWITCH Materials Inc. in 2007 and serves as its Chief Technology Officer. Dr. Branda's expertise lies at the interface of organic chemistry and materials science with a focus on designing and synthesizing molecular switches - molecules that change their structure and function when triggered with light, electricity or other stimuli. He is one of Canada's leading materials scientists, is a 2006 Canada's Top 40 Under 40 recipient, a 2005 NSERC Steacie Fellowship winner and a Tier I Canada Research Chair in Materials Science.
"We are a trans-disciplinary group of researchers who cross boundaries between synthetic organic chemistry, materials science, photochemistry, electrochemistry, nanotechnology, and bio-sciences. Our goals are to work in teams to enable technology."
"Our research program lies at the interface of organic chemistry and materials science with a focus on designing and synthesizing molecular switches – (molecules that change their structure and function when triggered with light, electricity or chemical stimuli) – and hybrid nanostructures. We work closely with materials scientists and the medical research community to deliver unprecedented designer photo switches to solve practical challenges in molecular photonics, electronics, therapeutics, and diagnostics."
"The program involves integrating photo- and electro-responsive molecules into digital data storage systems, synthetic reagents and catalysts, sensors and dosimeters and drug delivery systems, using light as a trigger to selectively unmask known drug architectures as well as using optics to control important metabolic intermediates and enzyme cofactors".
Dirk Lange, Ph.D. Microbiology & Immunology, UWO
Dr. Dirk Lange is a microbiologist who earned his Ph.D. (honours) in Microbiology and Immunology from the University of Western Ontario (London, Ontario) on understanding the role of the capsular polysaccharide in the pathogenesis of Campylobacter jejuni.
Dr. Lange completed his post-doctoral fellowship at The Stone Centre at VGH, where he contributed significantly to the area of urinary biomaterial design, providing a basic science perspective to understanding ureteral stent-related morbidity.
Dr. Lange is involved in collaborative work with Dr. Alan So (Urology, UBC) and Dr. John Smit (Microbiology, UBC) aimed at studying the use of non-pathogenic bacteria in the treatment of superficial bladder cancer. His current research interests at Vancouver General Hospital are in the area of ureteral stent associated morbidity, with specific emphasis on biomaterial design and the development of mechanisms that prevent bacterial adhesion, colonization and biofilm formation.
Rowland Hanson is chairman of CRH & Associates and the CEO of The HMC Company.
During his time with the Microsoft Corporation, Mr. Hanson named and successfully launched the WINDOWS brand.
Before his time with Microsoft, Hanson served as the Vice President of Worldwide Marketing for the Neutrogena Corporation. A leading skin care and cosmetics company, Neutrogena experienced incredible growth and was acquired in 1994 by Johnson & Johnson.
Hanson has served as a branding consultant for companies like Monsanto, IBM and Nautilus, which created BowFlex under his direction.
He is currently on the Board and a Trustee of the Microsoft Alumni Network.